Location History:
- Perry Hall, MA (US) (2011)
- Perry Hall, MD (US) (2010 - 2018)
Company Filing History:
Years Active: 2010-2018
Title: Innovations of Dechun Li in Pulmonary Research
Introduction
Dechun Li is a prominent inventor based in Perry Hall, MD (US), known for his significant contributions to the field of pulmonary research. With a total of five patents to his name, he has made remarkable strides in understanding and treating pulmonary conditions.
Latest Patents
Among his latest patents, Dechun Li has developed a method of promoting wound healing with a hypoxia-induced mitogenic factor (HIMF). His research indicates that FIZZ1/RELMα is inducible by hypoxia in the lung, with its expression found in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. The recombinant FIZZ1/RELMα protein has been shown to stimulate rat pulmonary microvascular smooth muscle cell (RPSM) proliferation in a dose-dependent manner. HIMF strongly activates Akt phosphorylation, and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits this activation, as well as HIMF-stimulated RPSM proliferation. This suggests that the PI3K/Akt pathway mediates the proliferative effect of HIMF, which also exhibits angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II. Another significant patent involves a method for treating pulmonary hypertension, further emphasizing the importance of HIMF in pulmonary health.
Career Highlights
Dechun Li is affiliated with The Johns Hopkins University, where he continues to advance his research and innovations in pulmonary medicine. His work has garnered attention for its potential impact on treating various pulmonary conditions.
Collaborations
Dechun Li collaborates with esteemed colleagues, including Roger A Johns and Xingwu Teng, contributing to a rich environment of innovation and research.
Conclusion
Dechun Li's innovative work in pulmonary research, particularly through his patents on HIMF, showcases his dedication to advancing medical science. His contributions have the potential to significantly improve treatment options for pulmonary conditions.